West Pharmaceutical Services, Inc. logo
WSTWest Pharmaceutical Services, Inc.

Free Cash Flow (FCF): $458.00M

The free cash flow (FCF) is $458.00M. It is above its 12-month average by 20.10% ($381.33M).

Free Cash Flow

WST Free Cash Flow (FCF)

$47.20M

Reported quarterly free cash flow; no daily interpolation.

-46.06% 5Y

WST Quarterly Free Cash Flow Growth (YoY)

Free Cash Flow growth vs the same quarter one year earlier, last 20 quarters.

WST Free Cash Flow (FCF)

WST Average Free Cash Flow (FCF) Chart

WST Free Cash Flow (FCF)

WST Current vs Average Free Cash Flow (FCF) Chart

WST Free Cash Flow (FCF) Metrics

FREE CASH FLOW (FCF)

$458.00M

FREE CASH FLOW (FCF) AVG TTM

$381.33M

FREE CASH FLOW (FCF) AVG 3Y

$383.10M

FREE CASH FLOW (FCF) AVG 5Y

$372.70M

FREE CASH FLOW (FCF) AVG 10Y

$270.34M

FREE CASH FLOW (FCF) AVG 15Y

$201.48M

FREE CASH FLOW (FCF) AVG 20Y

$158.04M

CURRENT VS TTM AVG

+20.10%

CURRENT VS 3Y AVG

+19.55%

CURRENT VS 5Y AVG

+22.89%

CURRENT VS 10Y AVG

+69.42%

CURRENT VS 15Y AVG

+127.31%

CURRENT VS 20Y AVG

+189.81%

FCF Analysis

Free Cash Flow (TTM)

$458.00M

FCF Yield

1.80%

Price/FCF

55.5

Formula: FCF = Operating Cash Flow - Capital Expenditures

Why FCF matters:

  • Shows actual cash available (not accounting earnings)
  • Funds dividends, buybacks, and debt reduction
  • Less susceptible to accounting manipulation than net income
  • Key metric for DCF valuation models

Free Cash Flow (FCF) Formula & Definition

Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Free Cash Flow (FCF) FAQ

What is the free cash flow (FCF) for West Pharmaceutical Services, Inc. (WST)?
The free cash flow (FCF) for WST stock is $458.00M.
What is the TTM average free cash flow (FCF) for West Pharmaceutical Services, Inc. (WST)?
The TTM average free cash flow (FCF) for WST stock is $381.33M.
What is the 3Y average free cash flow (FCF) for West Pharmaceutical Services, Inc. (WST)?
The 3Y average free cash flow (FCF) for WST stock is $383.10M.
What is the 5Y average free cash flow (FCF) for West Pharmaceutical Services, Inc. (WST)?
The 5Y average free cash flow (FCF) for WST stock is $372.70M.
What is the 10Y average free cash flow (FCF) for West Pharmaceutical Services, Inc. (WST)?
The 10Y average free cash flow (FCF) for WST stock is $270.34M.
What is the 15Y average free cash flow (FCF) for West Pharmaceutical Services, Inc. (WST)?
The 15Y average free cash flow (FCF) for WST stock is $201.48M.
What is the 20Y average free cash flow (FCF) for West Pharmaceutical Services, Inc. (WST)?
The 20Y average free cash flow (FCF) for WST stock is $158.04M.

WST Free Cash Flow (FCF) History

DATEFREE CASH FLOW (FCF)
2026-03-31$458.00M
2025-09-30$379.10M
2025-03-31$306.90M
2024-09-30$321.60M
2024-03-31$386.10M
2023-09-30$420.00M
2023-03-31$410.00M
2022-09-30$387.80M
2022-03-31$382.00M
2021-09-30$341.10M
2021-03-31$307.10M
2020-09-30$272.10M
2020-03-31$247.00M
2019-09-30$215.20M
2019-03-31$185.70M
2018-09-30$192.70M
2018-03-31$166.30M
2017-09-30$104.80M
2017-03-31$68.40M
2016-09-30$48.10M
2016-03-31$77.10M
2015-09-30$76.30M
2015-03-31$61.40M
2014-09-30$78.20M
2014-03-31$85.30M
2013-09-30$75.20M
2013-03-31$30.50M
2012-09-30$25.80M
2012-03-31$25.60M
2011-09-30$50.20M
2011-03-31$60.40M
2010-09-30$65.20M
2010-03-31$53.70M
2009-09-30$-1.00M
2009-03-31$-4.40M
2008-09-30$1.70M
2008-03-31$-8.10M
2007-09-30$-600000.00
2007-03-31$34.20M
2006-09-30$57.40M
2006-03-31$35.40M
2005-09-30$36.80M
2005-03-31$13.50M
2004-09-30$-3.30M
2004-03-31$-6.80M
2003-09-30$18.20M
2003-03-31$26.60M

About West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.

Exton, PA
10,600 employees
Healthcare / Medical - Instruments & Supplies
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Eric Green